Clinical Trial Update: Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of recombinant EphB4-HSA fusion protein with pembrolizumab has completed and results are posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Recombinant EphB4-HSA fusion protein (EphB4-HSA fusion protein)

Snippet

Sponsor: University of Southern California | Conditions: ALK Gene Mutation, BRAF Gene Mutation | Phase 2 | Status: COMPLETED | Results posted: 2025-10-22